ProMIS Neurosciences Inc.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company based in Toronto, Ontario, and Cambridge, Massachusetts. The company is dedicated to the discovery and development of selective antibody therapies targeting neurodegenerative and other misfolded protein diseases at their source, using innovative protein folding predictions and a proprietary target discovery engine called EpiSelect™.

Products & Services

PMN310 | Amyloid-Beta:A therapeutic candidate targeting amyloid-beta for the treatment of Alzheimer's disease.

PMN267 | TDP-43:A therapeutic candidate targeting TDP-43 for ALS, FTD, and LATE.

PMN442 | Alpha-Synuclein:A therapeutic candidate targeting alpha-synuclein for Parkinson's disease, MSA, and DLB.

Vaccines:Part of the product pipeline focused on neurodegenerative and misfolded protein diseases.

Specialties

Neurodegenerative Diseases Misfolded Protein Diseases Selective Antibody Therapies Precision Medicine Protein Folding Predictions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: PIPE T: - FT: PIPE	A: 175000000 MR: - FA: up to $175 million FAN: 175000000	D: 2026-01-30 FD: 2026-01-30	8 investors
2	RT: PIPE T: - FT: PIPE	A: 3000000 MR: - FA: approximately $3.0 million FAN: 3000000	D: 2025-07-28 FD: 2025-07-28	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 800000 MR: - FA: $0.8 million FAN: 800000	D: 2025-07-22 FD: 2025-07-22	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 2400000 MR: - FA: approximately $2.4 million FAN: 2400000	D: 2025-07-22 FD: 2025-07-22	1 investors
5	RT: Private Placement T: - FT: Private Placement	A: 30300000 MR: - FA: $30.3 million FAN: 30300000	D: 2024-07-26 FD: 2024-07-26	5 investors
6	RT: Private Placement T: - FT: Private Placement	A: 20400000 MR: - FA: $20.4 million FAN: 20400000	D: 2023-09-08 FD: 2023-09-08	1 investors
7	RT: Private Placement T: - FT: Private Placement	A: 20400000 MR: - FA: $20.4 million FAN: 20400000	D: 2023-08-21 FD: 2023-08-21	4 investors

PIPE Latest

2026-01-30

$175.0M

8 investors (Pro only)

PIPE 2025-07-28

$3.0M

Registered Direct Offering 2025-07-22

$800K

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Howard Fillit

Geriatrician, Neuroscientist, and Innovative Philanthropy Executive

S

Suzanne Hendrix

PhD

M

Michael Weiner

Professor Emeritus of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at UCSF

H

Henrik Zetterberg

Professor of Neurochemistry and Clinical Chemist

N

Neil R. Cashman

Chief Scientific Officer at ProMIS Neurosciences and Professor of Medicine at the University of British Columbia

S

Sharon Cohen

Medical Director and Principal Investigator

View 22 more team members with Pro

Unlock Full Team Directory

Recent News